Exact Mass: 389.279061

Exact Mass Matches: 389.279061

Found 177 metabolites which its exact mass value is equals to given mass value 389.279061, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

3-Geranylgeranylindole; 3-(Geranylgeranyl)indole

1H-Indole, 3-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)-

C28H39N (389.3082334)


   

N-Arachidonoyl GABA

4-{[(8Z,11Z,14Z)-1-hydroxyicosa-5,8,11,14-tetraen-1-ylidene]amino}butanoic acid

C24H39NO3 (389.29297840000004)


N-Arachidonoyl GABA is also known as N-Arachidonoyl-g-aminobutanoate or Elmiric acid. N-Arachidonoyl GABA is considered to be practically insoluble (in water) and acidic. N-Arachidonoyl GABA is a fatty amide lipid molecule

   

4-Hydroxydodecanedioylcarnitine

3-[(11-carboxy-4-hydroxyundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


4-Hydroxydodecanedioylcarnitine is an acylcarnitine. More specifically, it is an 4-Hydroxydodecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxydodecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxydodecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Hydroxydodecanedioylcarnitine

3-[(11-carboxy-10-hydroxyundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


10-Hydroxydodecanedioylcarnitine is an acylcarnitine. More specifically, it is an 10-Hydroxydodecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydodecanedioylcarnitine

3-[(11-carboxy-5-hydroxyundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


5-Hydroxydodecanedioylcarnitine is an acylcarnitine. More specifically, it is an 5-Hydroxydodecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydodecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydodecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxydodecanedioylcarnitine

3-[(11-carboxy-6-hydroxyundecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


6-Hydroxydodecanedioylcarnitine is an acylcarnitine. More specifically, it is an 6-Hydroxydodecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxydodecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxydodecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Eicosapentaenoyl Serine

3-hydroxy-2-(icosa-5,8,11,14,17-pentaenamido)propanoic acid

C23H35NO4 (389.25659500000006)


N-eicosapentaenoyl serine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Serine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-oleoyltaurine

2-{[(9Z)-octadec-9-enoyl]amino}ethane-1-sulphonic acid

C20H39NO4S (389.25996540000006)


   

(2S,3R)-3-Butan-2-yl-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-prop-2-enylbutanediamide

2-(Butan-2-yl)-3-(dihydroxycarbonimidoyl)-N-[1-(methyl-C-hydroxycarbonimidoyl)-2-phenylethyl]hex-5-enimidate

C21H31N3O4 (389.23144460000003)


   

Dalcetrapib

1-(2-Ethylbutyl)-N-{2-[(2-methylpropanoyl)sulphanyl]phenyl}cyclohexane-1-carboximidic acid

C23H35NO2S (389.23883700000005)


D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively[1][2].

   
   
   
   
   
   
   

tert-Butyl (3S)-3-{[(2-morpholinoethyl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate

tert-Butyl (3S)-3-{[(2-morpholinoethyl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate

C21H31N3O4 (389.23144460000003)


   
   
   

kalihinol F|kalihinol-F

kalihinol F|kalihinol-F

C23H39N3O2 (389.3042114)


   

(3RS,4RS,6RS,8aSR,9SR,10aSR)-6-ethyl-2,3,4,5,5,6,6,7,8,8a,9,10-dodecahydro-6-methoxy-2-methylspiro[1H-4,10a-methanopentaleno[1,6-cd]azonine-11,3(4H)-2H-pyran]-9-carboxylic acid|yuzuric acid

(3RS,4RS,6RS,8aSR,9SR,10aSR)-6-ethyl-2,3,4,5,5,6,6,7,8,8a,9,10-dodecahydro-6-methoxy-2-methylspiro[1H-4,10a-methanopentaleno[1,6-cd]azonine-11,3(4H)-2H-pyran]-9-carboxylic acid|yuzuric acid

C23H35NO4 (389.25659500000006)


   
   
   
   

2-octadec-7-enamidoethanesulfonic acid

2-octadec-7-enamidoethanesulfonic acid

C20H39NO4S (389.25996540000006)


   
   
   

N-oleoyl taurine

N-(9Z-octadecenoyl)-taurine

C20H39NO4S (389.25996540000006)


   
   
   
   
   
   
   
   

EMA-21

N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-L-gamma-amino butyric acid

C24H39NO3 (389.29297840000004)


   

Sphingofungin B

2S-amino-3R,4R,5S,14R-tetrahydroxyeicos-6E-enoic acid

C20H39NO6 (389.2777234)


   

NA 24:5;O2

N-[2-(3,4-dihydroxyphenyl)ethyl]-9Z-hexadecenamide

C24H39NO3 (389.29297840000004)


   

1-Phenyl-8-[(1S,2S)-2-phenylcyclohexyl]-1,3,8-triazaspiro[4.5]decan-4-one

1-Phenyl-8-[(1S,2S)-2-phenylcyclohexyl]-1,3,8-triazaspiro[4.5]decan-4-one

C25H31N3O (389.2466996)


   

β-Hydroxy Tamoxifen

β-Hydroxy Tamoxifen

C26H31NO2 (389.2354666)


   

TERT-BUTYL 4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLATE

TERT-BUTYL 4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLATE

C20H32BN3O4 (389.2485742)


   

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-

C24H36FNO2 (389.2729928)


   

1-[4-(2-dimethylamino-ethoxy)phenyl]-1,2-diphenyl-1-butanol

1-[4-(2-dimethylamino-ethoxy)phenyl]-1,2-diphenyl-1-butanol

C26H31NO2 (389.2354666)


   

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-, (aS,4S)- (9CI)

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-, (aS,4S)- (9CI)

C24H36FNO2 (389.2729928)


   

Methylrosaniline

Methylrosaniline

C25H31N3O (389.2466996)


G - Genito urinary system and sex hormones > G01 - Gynecological antiinfectives and antiseptics > G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use

   

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-, (aR,4R)- (9CI)

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-, (aR,4R)- (9CI)

C24H36FNO2 (389.2729928)


   

1-[4-[2-(diethylamino)ethoxy]phenyl]-1,2-diphenylethanol

1-[4-[2-(diethylamino)ethoxy]phenyl]-1,2-diphenylethanol

C26H31NO2 (389.2354666)


   

6-(4-Boc-1-piperazinyl)pyridine-3-boronic acid pinacol ester

6-(4-Boc-1-piperazinyl)pyridine-3-boronic acid pinacol ester

C20H32BN3O4 (389.2485742)


   
   

dodecyl 2-acetamido-2-deoxy-beta-d-glucopyranoside

dodecyl 2-acetamido-2-deoxy-beta-d-glucopyranoside

C20H39NO6 (389.2777234)


   

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-, (aR,4S)-rel- (9CI)

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-pentyl-, (aR,4S)-rel- (9CI)

C24H36FNO2 (389.2729928)


   

(1-CBZ-PIPERIDIN-4-YL-AZETIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER

(1-CBZ-PIPERIDIN-4-YL-AZETIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER

C21H31N3O4 (389.23144460000003)


   

2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)pyridine-3-boronic acid pinacol ester

2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)pyridine-3-boronic acid pinacol ester

C20H32BN3O4 (389.2485742)


   

benzyl 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]azetidin-1-yl]piperidine-1-carboxylate

benzyl 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]azetidin-1-yl]piperidine-1-carboxylate

C21H31N3O4 (389.23144460000003)


   
   

Dalcetrapib

Dalcetrapib

C23H35NO2S (389.23883700000005)


D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively[1][2].

   

7-Oxolithocholate

7-Oxolithocholate

C24H37O4- (389.2691702)


A bile acid anion that is the conjugate base of 7-oxolithocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

19-(4-Hydroxyphenyl)nonadecanoate

19-(4-Hydroxyphenyl)nonadecanoate

C25H41O3- (389.30555360000005)


   

12alpha-Hydroxy-3-oxo-5beta-cholan-24-Oate

12alpha-Hydroxy-3-oxo-5beta-cholan-24-Oate

C24H37O4- (389.2691702)


A bile acid anion that is the conjugate base of 12alpha-hydroxy-3-oxo-5beta-cholan-24-oic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

7alpha-Hydroxy-3-oxo-5beta-cholan-24-Oate

7alpha-Hydroxy-3-oxo-5beta-cholan-24-Oate

C24H37O4- (389.2691702)


A bile acid anion that is the conjugate base of 7alpha-hydroxy-3-oxo-5beta-cholan-24-oic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

12-Dehydrodeoxycholate

12-Dehydrodeoxycholate

C24H37O4- (389.2691702)


   

7beta-Hydroxy-3-oxo-5beta-cholanate

7beta-Hydroxy-3-oxo-5beta-cholanate

C24H37O4- (389.2691702)


   
   
   
   
   

(2S,3R)-3-Butan-2-yl-N-hydroxy-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-prop-2-enylbutanediamide

(2S,3R)-3-Butan-2-yl-N-hydroxy-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-prop-2-enylbutanediamide

C21H31N3O4 (389.23144460000003)


   

N-Arachidonoyl-gamma-aminobutanoate

N-Arachidonoyl-gamma-aminobutanoate

C24H39NO3 (389.29297840000004)


   
   
   

3beta-Hydroxy-7-oxo-5beta-cholan-24-oate

3beta-Hydroxy-7-oxo-5beta-cholan-24-oate

C24H37O4- (389.2691702)


   
   
   
   

2-(methylamino)-N-[3-methyl-1-oxo-1-[2-[oxo-(phenylhydrazo)methyl]-1-pyrrolidinyl]butan-2-yl]propanamide

2-(methylamino)-N-[3-methyl-1-oxo-1-[2-[oxo-(phenylhydrazo)methyl]-1-pyrrolidinyl]butan-2-yl]propanamide

C20H31N5O3 (389.2426776)


   

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3R,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2S,3R,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3R,6R)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2R,3R,6R)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3S,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2S,3S,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide

N-[(2S,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide

N-[(2R,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-1,5-benzoxazocin-6-one

(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-1,5-benzoxazocin-6-one

C22H35N3O3 (389.267828)


   

N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-1,5-benzoxazocin-6-one

(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-1,5-benzoxazocin-6-one

C22H35N3O3 (389.267828)


   

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3S,6R)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2R,3S,6R)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3R,6R)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2S,3R,6R)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3S,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2R,3S,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[(2R,3R,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

N-[(2R,3R,6S)-6-[2-[[cyclohexyl(oxo)methyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]acetamide

C21H31N3O4 (389.23144460000003)


   

N-[(2S,3S,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide

N-[(2S,3S,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-pyridinecarboxamide

C21H31N3O4 (389.23144460000003)


   

N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(1-oxopropyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-2-(4-morpholinyl)acetamide

N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(1-oxopropyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-2-(4-morpholinyl)acetamide

C21H31N3O4 (389.23144460000003)


   

N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(1-oxopropyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-2-(4-morpholinyl)acetamide

N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(1-oxopropyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-2-(4-morpholinyl)acetamide

C21H31N3O4 (389.23144460000003)


   

N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(1-oxopropyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-2-(4-morpholinyl)acetamide

N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(1-oxopropyl)-3-phenyl-2-azetidinyl]methyl]-N-methyl-2-(4-morpholinyl)acetamide

C21H31N3O4 (389.23144460000003)


   

(1R,5S)-N-cyclohexyl-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1R,5S)-N-cyclohexyl-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C25H31N3O (389.2466996)


   
   
   
   

(3R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxytetradecanoate

(3R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxytetradecanoate

C20H37O7- (389.2539152)


   

(3R,13R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxytetradecanoate

(3R,13R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxytetradecanoate

C20H37O7- (389.2539152)


   

(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

C24H39NO3 (389.29297840000004)


   
   
   
   

4-(2-Hexanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(2-Hexanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


   

4-(3-Butanoyloxy-2-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Butanoyloxy-2-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


   

4-(3-Acetyloxy-2-heptanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Acetyloxy-2-heptanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C19H35NO7 (389.24134000000004)


   

1,3-DI-O-Trimethylsilyl tetradecasphinganine

1,3-DI-O-Trimethylsilyl tetradecasphinganine

C20H47NO2Si2 (389.31451619999996)


   

1H-Indole, 3-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)-

1H-Indole, 3-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)-

C28H39N (389.3082334)


   

NAGABA

N-Arachidonoyl-γ-aminobutyric acid

C24H39NO3 (389.29297840000004)


   

bhas#24(1-)

bhas#24(1-)

C20H37O7 (389.2539152)


Conjugate base of bhas#24

   

digoxigenin(1-)

digoxigenin(1-)

C23H33O5 (389.23278680000004)


An organic anion that is the conjugate base of digoxigenin resulting from the deprotonation of the furanone moiety; major species at pH 7.3.

   

bhos#24(1-)

bhos#24(1-)

C20H37O7 (389.2539152)


Conjugate base of bhos#24

   

N-arachidonoyl-gamma-aminobutyric acid

N-arachidonoyl-gamma-aminobutyric acid

C24H39NO3 (389.29297840000004)


An N-acyl-gamma-aminobutyric acid resulting from the formal condensation of the amino group of gamma-aminobutyric acid with the carboxy group of arachidonic acid.

   

N-oleoyltaurine

N-oleoyltaurine

C20H39NO4S (389.25996540000006)


A fatty acid-taurine conjugate derived from oleic acid.

   
   
   
   
   
   
   
   
   
   
   
   

(1's,3r,5'r,6s,11's,12's)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

(1's,3r,5'r,6s,11's,12's)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

C23H35NO4 (389.25659500000006)


   

albovionitine

NA

C23H35NO4 (389.25659500000006)


{"Ingredient_id": "HBIN015091","Ingredient_name": "albovionitine","Alias": "NA","Ingredient_formula": "C23H35NO4","Ingredient_Smile": "NA","Ingredient_weight": "389.53","OB_score": "NA","CAS_id": "138935-81-6","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7048","PubChem_id": "NA","DrugBank_id": "NA"}

   

(2z,6e,12e,14e)-n-(1,3-dihydroxypropan-2-yl)-12-methylicosa-2,6,12,14,19-pentaenimidic acid

(2z,6e,12e,14e)-n-(1,3-dihydroxypropan-2-yl)-12-methylicosa-2,6,12,14,19-pentaenimidic acid

C24H39NO3 (389.29297840000004)


   

n-[(1s)-1-[(5-carbamimidamido-1-oxopentan-2-yl)-c-hydroxycarbonimidoyl]-2-phenylethyl]-3-methylbutanimidic acid

n-[(1s)-1-[(5-carbamimidamido-1-oxopentan-2-yl)-c-hydroxycarbonimidoyl]-2-phenylethyl]-3-methylbutanimidic acid

C20H31N5O3 (389.2426776)


   

methyl (1's,3r,5'r,6s,11's,12's)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1's,3r,5'r,6s,11's,12's)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H35NO4 (389.25659500000006)


   

(2s,3r,4r,5s,6e)-2-amino-3,4,5,14-tetrahydroxyicos-6-enoic acid

(2s,3r,4r,5s,6e)-2-amino-3,4,5,14-tetrahydroxyicos-6-enoic acid

C20H39NO6 (389.2777234)


   

(1s,2r,3r,4s,5r,8s,9s,10r,13s,16s,17r)-11-ethyl-16-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-6-ene-4,8-diol

(1s,2r,3r,4s,5r,8s,9s,10r,13s,16s,17r)-11-ethyl-16-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-6-ene-4,8-diol

C23H35NO4 (389.25659500000006)


   

2,5-dimethyl-8-{2-methyl-5-[2-(methylideneamino)propan-2-yl]oxolan-2-yl}-1,5-bis(methylideneamino)-octahydronaphthalen-2-ol

2,5-dimethyl-8-{2-methyl-5-[2-(methylideneamino)propan-2-yl]oxolan-2-yl}-1,5-bis(methylideneamino)-octahydronaphthalen-2-ol

C23H39N3O2 (389.3042114)


   

10-hydroxy-5-{[(2-hydroxyethyl)(methyl)amino]methyl}-5-(hydroxymethyl)-11-methylidenepentacyclo[10.3.2.0¹,⁶.0⁹,¹⁴.0⁹,¹⁶]heptadecan-15-one

10-hydroxy-5-{[(2-hydroxyethyl)(methyl)amino]methyl}-5-(hydroxymethyl)-11-methylidenepentacyclo[10.3.2.0¹,⁶.0⁹,¹⁴.0⁹,¹⁶]heptadecan-15-one

C23H35NO4 (389.25659500000006)


   

methyl (1's,3r,5'r,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1's,3r,5'r,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H35NO4 (389.25659500000006)


   

methyl (1's,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1's,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H35NO4 (389.25659500000006)


   

3-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1h-indole

3-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1h-indole

C28H39N (389.3082334)


   

methyl 6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl 6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H35NO4 (389.25659500000006)


   

(1r,2r,4as,5s,8s,8as)-2,5-dimethyl-8-[(2r,5s)-2-methyl-5-[2-(methylideneamino)propan-2-yl]oxolan-2-yl]-1,5-bis(methylideneamino)-octahydronaphthalen-2-ol

(1r,2r,4as,5s,8s,8as)-2,5-dimethyl-8-[(2r,5s)-2-methyl-5-[2-(methylideneamino)propan-2-yl]oxolan-2-yl]-1,5-bis(methylideneamino)-octahydronaphthalen-2-ol

C23H39N3O2 (389.3042114)


   

methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H35NO4 (389.25659500000006)


   

(1s,5s,6r,9s,10s,12r,14s,16r)-10-hydroxy-5-{[(2-hydroxyethyl)(methyl)amino]methyl}-5-(hydroxymethyl)-11-methylidenepentacyclo[10.3.2.0¹,⁶.0⁹,¹⁴.0⁹,¹⁶]heptadecan-15-one

(1s,5s,6r,9s,10s,12r,14s,16r)-10-hydroxy-5-{[(2-hydroxyethyl)(methyl)amino]methyl}-5-(hydroxymethyl)-11-methylidenepentacyclo[10.3.2.0¹,⁶.0⁹,¹⁴.0⁹,¹⁶]heptadecan-15-one

C23H35NO4 (389.25659500000006)


   

methyl (1r,3r,4r,7r,10s,14s,15r,18r,19s,20s)-20-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosane-3-carboxylate

methyl (1r,3r,4r,7r,10s,14s,15r,18r,19s,20s)-20-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosane-3-carboxylate

C23H35NO4 (389.25659500000006)


   

2-amino-n-[4-amino-3-({3-amino-6-[(methylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide

2-amino-n-[4-amino-3-({3-amino-6-[(methylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide

C17H35N5O5 (389.26380600000005)


   

(1's,3r,5'r,6r,11's,12's)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

(1's,3r,5'r,6r,11's,12's)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

C23H35NO4 (389.25659500000006)